Natalizumab - Medication and Pregnancy KB

Natalizumab

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S3778 R8078	Portaccio (control exposed to IFN), 2018	Malformations (minor and major)	early pregnancy	prospective cohort	unexposed, sick	Adjustment: No	5.51 [1.10;27.66] ^C	7/54 2/76	9	54		ref
S3777 R8064	Portaccio (control unexposed, sick), 2018	Malformations (minor and major)	early pregnancy	prospective cohort	unexposed, sick excluded	Adjustment: No	8.12 [2.62;25.19] ^C excluded (control group)	7/54 6/333	13	54		ref
S3770 R8057	Ebrahimi (control unexposed, disease free), 2015	All anomalies	3 months or more before pregnancy or1st trimester	prospective cohort	unexposed, disease free excluded	Adjustment: No	0.95 [0.25;3.68] ^C excluded (control group)	4/77 5/92	9	77		ref
S3769 R8050	Ebrahimi (control unexposed, sick), 2015	All anomalies	3 months or more before pregnancy or1st trimester excluded	prospective cohort	unexposed, sick	Adjustment: No	1.21 [0.26;5.59] ^C excluded (exposition period)	4/77 3/69	7	77		ref
					Total	1 studies	5.51 [1.10;27.66]		9	54
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: control exposed to IFN;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3770, 3777